{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:31:28Z","timestamp":1763415088140,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["VIR\/18\/2018\/ECD-I"],"award-info":[{"award-number":["VIR\/18\/2018\/ECD-I"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jceh.2023.101314","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T08:48:17Z","timestamp":1702111697000},"page":"101314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sofosbuvir\/Velpatasvir\/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India"],"prefix":"10.1016","volume":"14","author":[{"given":"Harshita","family":"Katiyar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrunal","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameet K.","family":"Mandot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-9381","authenticated-orcid":false,"given":"Amit","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0402-5534","authenticated-orcid":false,"given":"Surender","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajani","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prachi","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radha K.","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2023.101314_bib2","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org [As accessed on 10th July 2023]."},{"key":"10.1016\/j.jceh.2023.101314_bib3","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jceh.2016.07.001","article-title":"Indian National Association for Study of the Liver (INASL) guidance for antiviral therapy against HCV infection: update 2016","volume":"6","author":"Puri","year":"2016","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib5","first-page":"g3308","article-title":"Antiviral treatment of hepatitis C","volume":"348","author":"Feeney","year":"2014","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.jceh.2023.101314_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2016.08.021","article-title":"Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients","volume":"66","author":"Pol","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12664-017-0763-3","article-title":"Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: an Indian experience","volume":"36","author":"Goel","year":"2017","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2023.101314_bib8","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s40121-022-00666-0","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir as a hepatitis C virus infection salvage therapy in the real world: a systematic review and meta-analysis","volume":"11","author":"Xie","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jceh.2023.101314_bib9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jceh.2021.06.023","article-title":"Use of sofosbuvir\/velpatasvir\/voxilaprevir for sofosbuvir nonresponder genotype 3 HCV infection in India","volume":"12","author":"Tiwari","year":"2022","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib10","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jceh.2022.06.002","article-title":"Liver stiffness is reduced to normal after successful renal transplantation: a prospective cohort study","volume":"12","author":"Bhadauria","year":"2022","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285725","article-title":"Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-na\u00efve non-cirrhotic patients with chronic hepatitis C virus infection: study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial)","volume":"18","author":"Awasthi","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2023.101314_bib12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jceh.2018.07.004","article-title":"New direct-acting antivirals for the treatment of patients with hepatitis C virus infection: a systematic review of randomized controlled trials","volume":"9","author":"Pecoraro","year":"2019","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib13","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/jvh.12989","article-title":"Findings from a large Asian chronic hepatitis C real-life study","volume":"25","author":"Lim","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jceh.2023.101314_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6054677","article-title":"Determination of risk factors associated with the failure of 12 Weeks of direct-acting antiviral therapy in patients with hepatitis C: a prospective study","volume":"2022","author":"Nguyen Thi Thu","year":"2022","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jceh.2023.101314_bib15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/liv.14849","article-title":"Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: a real-world nationwide hepatitis C virus registry programme in Taiwan","volume":"41","author":"Chen","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2023.101314_bib16","doi-asserted-by":"crossref","first-page":"e3288","DOI":"10.1093\/cid\/ciaa1318","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir\/voxilaprevir for hepatitis C virus (HCV) NS5A-inhibitor experienced patients with difficult to cure characteristics","volume":"73","author":"Papaluca","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jceh.2023.101314_bib17","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1111\/liv.15075","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis","volume":"41","author":"Patel","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2023.101314_bib18","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S2468-1253(21)00399-X","article-title":"Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial","volume":"7","author":"Gupta","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib19","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4254\/wjh.v12.i12.1341","article-title":"Safety and efficacy of sofosbuvir\/velpatasvir\/voxilaprevir in post-liver transplant patients with previous direct-acting antiviral failure: six case reports","volume":"12","author":"Higley","year":"2020","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jgh.14466","article-title":"Burden of hepatitis C virus infection in India: a systematic review and meta-analysis","volume":"34","author":"Goel","year":"2019","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib21","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/jgh.15827","article-title":"Seroprevalence and burden of hepatitis C virus infection in WHO South-East Asia Region: a systematic review","volume":"37","author":"Goel","year":"2022","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib22","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jceh.2022.06.003","article-title":"A\u00a0systematic review of risk factors for hepatitis C virus infection among low-risk population in India","volume":"12","author":"Shalimar","year":"2022","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib23","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/jgh.13628","article-title":"Results of sofosbuvir-based combination therapy for chronic hepatitis C cohort of Indian patients in real-life clinical practice","volume":"32","author":"Sood","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2023.03.007","article-title":"Hepatitis C retreatment with first-line direct acting antiviral drugs","author":"Goel","year":"2023","journal-title":"J\u00a0Clin Exp Hepatol (Early online)"},{"key":"10.1016\/j.jceh.2023.101314_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4103\/ijn.IJN_259_21","article-title":"Rescue use of pegylated interferon in dialysis patient who failed to respond sofosbuvir","volume":"33","author":"Katiyar","year":"2023","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.jceh.2023.101314_bib26","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/jgh.15918","article-title":"Treatment outcomes of sofosbuvir\/velpatasvir\/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: real-world data from a multicenter Asian registry","volume":"37","author":"Wong","year":"2022","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib27","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","volume":"71","author":"Llaneras","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib28","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.101314_bib29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jhep.2023.04.011","article-title":"A\u00a0randomized controlled trial of SOF\/VEL\/VOX with or without ribavirin for retreatment of chronic hepatitis C","volume":"79","author":"El-Kassas","year":"2023","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688323008472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688323008472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:11:48Z","timestamp":1760854308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688323008472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0973688323008472"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2023.101314","relation":{},"ISSN":["0973-6883"],"issn-type":[{"type":"print","value":"0973-6883"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sofosbuvir\/Velpatasvir\/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2023.101314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101314"}}